Cempra (CEMP) was annihilated on October 16th because in the reporting of the drug Solithromyocin's success in trials, increased pain at the injection point was noted. Essentially what happened n what should have been a positive note, ws that the hedge funds flinched, and sold off. this caused the stock to plummet from 26.78 on October 15, 2015 to 15.76 on October 22, 2015. Since then, myself and my team have purchase more shares. This drug, represents a new non antibiotic that the FDA desperately wants to see approved. Barring an unforeseen setback in the trials (which is always possible), I see this stock above 40 around April of 16.